Vertex Pharmaceuticals is laying off workers and consolidating its real estate footprint in Rhode Island after ending a ...

Vertex is trimming its Rhode Island footprint on the back of a scrapped “cells plus device” program in diabetes, leaving 125 staffers out of a job. | The company is merging its three buildings at its ...

The layoffs will heavily affect Vertex’s operations in Rhode Island, where the biotech will consolidate three facilities into ...

NBC Securities recently dipped its toe into the biotech pool by purchasing 345 shares of Vertex Pharmaceuticals, valued at $167,000. Several other institutional investors followed suit, tweaking their ...

Vertex Pharmaceuticals continues to dominate biotech with its cystic fibrosis breakthroughs and pioneering gene-editing and ...

As a company, Vertex says, “We strike at the core of serious diseases to change people’s lives. Bringing together the ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

RBC Capital Markets is acting as the sole underwriter for the offering. RBC Capital Markets proposes to offer the shares of common stock from time to time to purchasers directly or through agents ...